APTO
Price:
$0.1925
Market Cap:
$11.46M
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, which is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic...[Read more]
Industry
Biotechnology
IPO Date
1992-03-16
Stock Exchange
NASDAQ
Ticker
APTO
According to Aptose Biosciences Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.07. This represents a change of -83.16% compared to the average of -0.42 of the last 4 quarters.
The mean historical PE Ratio of Aptose Biosciences Inc. over the last ten years is -40.23. The current -0.07 PE Ratio has changed -82.60% with respect to the historical average. Over the past ten years (40 quarters), APTO's PE Ratio was at its highest in in the March 2023 quarter at -0.08. The PE Ratio was at its lowest in in the December 2019 quarter at -0.72.
Average
-40.23
Median
-0.24
Minimum
-399.83
Maximum
-0.09
Discovering the peaks and valleys of Aptose Biosciences Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 93.06%
Maximum Annual PE Ratio = -0.09
Minimum Annual Increase = -99.95%
Minimum Annual PE Ratio = -399.83
Year | PE Ratio | Change |
---|---|---|
2023 | -0.34 | 285.56% |
2022 | -0.09 | -29.26% |
2021 | -0.12 | -71.87% |
2020 | -0.44 | -40.80% |
2019 | -0.74 | 400.97% |
2018 | -0.15 | -48.89% |
2017 | -0.29 | 238.43% |
2016 | -0.09 | -55.26% |
2015 | -0.19 | -99.95% |
2014 | -399.83 | 93.06% |
The current PE Ratio of Aptose Biosciences Inc. (APTO) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-0.18
5-year avg
-0.34
10-year avg
-40.23
Aptose Biosciences Inc.’s PE Ratio is less than CytomX Therapeutics, Inc. (6.89), greater than Instil Bio, Inc. (-1.86), greater than Neoleukin Therapeutics, Inc. (-5.86), less than Spero Therapeutics, Inc. (20.30), greater than Assembly Biosciences, Inc. (-2.39), greater than Fortress Biotech, Inc. (-0.77), greater than Mustang Bio, Inc. (-0.32), greater than Achilles Therapeutics plc (-0.60), greater than Fortress Biotech, Inc. (-0.77), greater than Gain Therapeutics, Inc. (-2.07), less than TFF Pharmaceuticals, Inc. (-0.02), greater than aTyr Pharma, Inc. (-2.33), greater than IN8bio, Inc. (-0.43), greater than Lantern Pharma Inc. (-2.05), greater than Affimed N.V. (-0.45), greater than Leap Therapeutics, Inc. (-2.00), greater than Adaptimmune Therapeutics plc (-3.59), greater than Corvus Pharmaceuticals, Inc. (-9.48), greater than Longboard Pharmaceuticals, Inc. (-30.61), less than TRACON Pharmaceuticals, Inc. (0.02), less than Oncternal Therapeutics, Inc. (-0.05), greater than Aeglea BioTherapeutics, Inc. (-5.66),
Company | PE Ratio | Market cap |
---|---|---|
6.89 | $87.65M | |
-1.86 | $139.85M | |
-5.86 | $8.20M | |
20.30 | $59.97M | |
-2.39 | $97.57M | |
-0.77 | $54.93M | |
-0.32 | $9.99M | |
-0.60 | $40.69M | |
-0.77 | $58.73M | |
-2.07 | $44.30M | |
-0.02 | $288.80K | |
-2.33 | $131.12M | |
-0.43 | $21.06M | |
-2.05 | $39.15M | |
-0.45 | $33.20M | |
-2.00 | $119.94M | |
-3.59 | $161.59M | |
-9.48 | $519.20M | |
-30.61 | $2.34B | |
0.02 | $109.72K | |
-0.05 | $1.56M | |
-5.66 | $48.63M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Aptose Biosciences Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Aptose Biosciences Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Aptose Biosciences Inc.'s PE Ratio?
How is the PE Ratio calculated for Aptose Biosciences Inc. (APTO)?
What is the highest PE Ratio for Aptose Biosciences Inc. (APTO)?
What is the 3-year average PE Ratio for Aptose Biosciences Inc. (APTO)?
What is the 5-year average PE Ratio for Aptose Biosciences Inc. (APTO)?
How does the current PE Ratio for Aptose Biosciences Inc. (APTO) compare to its historical average?